| Literature DB >> 28542622 |
Marcelo Aldrighi Moreira1,2, Luiza Silveira Lessa1,3, Francieli Regina Bortoli4, Abigail Lopes1,2, Eduardo Picolo Xavier2, Renan Antonio Ceretta3, Fernanda Guglielmi Faustini Sônego3, Cristiane Damiani Tomasi1, Patricia Duarte Simões Pires3, Luciane Bisognin Ceretta1,2,3, Ingrid Dalira Schweigert Perry1, Priscyla Waleska Simões1,2,3,5.
Abstract
OBJECTIVE: To establish the diagnostic accuracy of magnetic resonance imaging (MRI) as an auxiliary means for the diagnosis of oral cancer through a systematic review and meta-analysis.Entities:
Mesh:
Year: 2017 PMID: 28542622 PMCID: PMC5443513 DOI: 10.1371/journal.pone.0177462
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of included studies–MRIs.
| Author/year | Country | Continent | Cancer cases | Lesion number | Not ill | Tumour site | Tumour type | Tesla | Design | Test site | Gender | Mean | Total number of individuals | Prevalence |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aghaghazviniet al. 2015 (DCE MRI)[ | Iran | Asia | 10 | 46 | 36 | Major salivary glands | Carcinoma and Adenocarcinoma | 3.0 T | Retrospective | University | 22 (Male) / 24 (Fem) | Not indicated | 46 | 21.7% |
| Ai et al. 2013 (DCE and DW MRI)[ | China | Asia | 33 | 46 | 13 | Tongue | Carcinoma | 1.5 T | Retrospective | Hospital | 23 (Male) / 10 (Fem) | 35 | 33 | 71.7% |
| Alibek et al. 2007 (DW and traditional MRI)[ | Germany | Europe | 13 | 112 | 99 | Parotid gland | Carcinoma | 1.5 T | Retrospective | Not indicated | 55 (Male) / 57 (Fem) | 54 | 112 | 11.6% |
| Bartels et al. 2000 (traditional MRI)[ | USA | America | 17 | 35 | 18 | Parotid gland | Carcinoma | Not indicated | Retrospective | Hospital | Not indicated | Not indicated | Not indicated | 44.8% |
| Christe et al. 2011 (traditional MRI)[ | USA | America | 27 | 84 | 57 | Parotid gland | Carcinoma | 1.5 T | Retrospective | Hospital | 43 (Male) / 41 (Fem) | 56.0 | 84 | 32.1% |
| Eida et al. 2007 (DW MRI)[ | Japan | Asia | 9 | 31 | 22 | Salivary glands | Carcinoma and Adenocarcinoma | 1.5 T | Retrospective | Not indicated | 13 (Male) / 18 (Fem) | 63 | 31 | 29.0% |
| Fassnacht et al. 2013 (traditional MRI)[ | Belgium | Europe | 20 | 133 | 113 | Parotid gland | Carcinoma | 1.5 T/3 T | Retrospective | University | Not indicated | Not indicated | Not indicated | 15.0% |
| Hisatomi et al. 2007 (DCE MRI)[ | Japan | Asia | 12 | 46 | 35 | Salivary glands | Carcinoma | 1.5 T | Retrospective | Hospital | 15 (Male) / 21 (Fem) | 56.8 | 36 | 26.0% |
| Inci et al. 2010 (DW MRI)[ | Turkey | Asia | 8 | 25 | 17 | Parotid gland | Carcinoma | 1.5 T | Retrospective | Not indicated | 13 (Male) / 9 (Fem) | 44 | 22 | 32.0% |
| Inohara et al. 2008 (traditional MRI)[ | Japan | Asia | 21 | 81 | 60 | Parotid gland | Carcinoma | 1.0T | Retrospective | Hospital | Not indicated | Not indicated | Not indicated | 22.5% |
| Kato et al. 2015 (DW MRI)[ | Japan | Asia | 9 | 31 | 22 | Parotid gland | Carcinoma | 3 T | Retrospective | Hospital | 17 (Male) / 14 (Fem) | 63 | 31 | 29.0% |
| Lam et al. 2015 (DCE and traditional MRI)[ | Japan | Asia | 24 | 98 | 74 | Salivary glands | Carcinoma and Adenocarcinoma | 1.5 T | Retrospective | Hospital | 36 (Male) / 62 (Fem) | 53 | 98 | 24.4% |
| Matsuzaki et al. 2012 (DCE MRI)[ | Japan | Asia | 15 | 32 | 17 | Minor salivary glands | Carcinoma | 1.5 T | Retrospective | Not indicated | 16 (Male) / 16 (Fem) | 57.8 | 32 | 46.8% |
| Motoori et al. 2005 (DW MRI)[ | Japan | Asia | 5 | 33 | 28 | Parotid gland | Carcinoma | 1.5 T | Retrospective | Not | 26 (Male) / 7 (Fem) | 60 | 33 | 15.1% |
| Paris et al. 2005 (traditional MRI)[ | France | Europe | 15 | 86 | 71 | Parotid gland | Carcinoma | 1.5 T | Retrospective | Hospital | 83 (Male) / 98 (Fem) | 55.2 | 181 | 17.4% |
| Prades et al. 2007 (traditional MRI)[ | France | Europe | 13 | 69 | 56 | Parotid gland | Carcinoma | 1.0T/1.5 T | Retrospective | Not indicated | 29 (Male) / 39 (Fem) | 55.1 | 68 | 19.1% |
| Rudack et al. 2007 (traditional MRI)[ | Germany | Europe | 30 | 109 | 79 | Salivary glands | Not indicated | 1.0T/1.5 T | Retrospective | Not indicated | 61 (Male) / 48 (Fem) | 55.4 | 109 | 27.5% |
| Sakamoto et al. 2014 (traditional MRI)[ | Japan | Asia | 34 | 100 | 66 | Parotid gland | Carcinoma | 1.5 T | Retrospective | Hospital | 45 (Male) / 55 (Fem) | 55.6 | 100 | 34.0% |
| Sumi et al. 2012 (DW MRI)[ | Japan | Asia | 11 | 31 | 20 | Salivary glands | Not indicated | 1.5 T | Retrospective | Hospital | 16 (Male) / 15 (Fem) | 61 | 31 | 35.4% |
| Sumi et al. 2014 (DW and DCE MRI)[ | Japan | Asia | 14 | 36 | 22 | Not indicated | Lymphoma and Carcinoma | 1.5 T | Retrospective | Hospital | Not indicated | Not indicated | Not indicated | 38.8% |
| Takashima et al. 1997 (traditional MRI)[ | Japan | Asia | 14 | 53 | 39 | Parotid gland | Carcinoma | 1.5 T | Retrospective | Hospital | 25 (Male) / 28 (Fem) | 55.3 | 53 | 26.4% |
| Turner et al. 2008 (DW and traditional MRI)[ | France | Europe | 7 | 29 | 22 | Parotid gland | Carcinoma and Adenocarcinoma | Not indicated | Retrospective | Not indicated o | 17 (Male) / 12 (Fem) | 47 | 29 | 24.1% |
| Yabuuchi et al. 2003 (DCE MRI)[ | Japan | Asia | 11 | 33 | 22 | Salivary glands | Carcinoma and Adenocarcinoma | 0.5 T | Retrospective | Not indicated | 13 (Male) / 16 (Fem) | 59 | 29 | 33.3% |
| Yerli et al. 2010 (traditional MRI)[ | Turkey | Asia | 5 | 25 | 20 | Parotid gland | Carcinoma | 1.5 T | Retrospective | Hospital | 9 (Male) / 16 (Fem) | 66.1 | 25 | 20.0% |
Summary of diagnostic measures.
| MRI | Diagnostic measures | Diagnostic threshold | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Sensitivity (95% CI) | Specificity | DOR | AUC | rs | P | B | P | ROC panel | |
| DW MRI | 76.4% (67.3%-83.9%) | 91.3% (87.3%-94.4%) | 30.7 (12.7–74.3) | 0.917 (0.915–0.918) | -0.168 | 0.666 | 0.018 | 0.9569 | No diagnostic threshold effect |
| DCE MRI | 84.0% (76.2%-90.1%) | 89.5% (84.7%-93.2%) | 48.1 (22.4–103.2) | 0.936 (0.934–0.937) | 0.577 | 0.175 | -0.086 | 0.7936 | No diagnostic threshold effect |
| Traditional MRI | 72.5% (66.4%-78.0%) | 86.6% (84.0%-88.9%) | 23.9 (13.2–43.3) | 0.894 (0.894–0.895) | 0.610 | -0.085 | 0.6373 | No diagnostic threshold effect | |
*statistically significant (p<0.05).
Fig 2Measures of diagnostic performance.
Sensitivity analysis.
| Sensitivity analysis | Meta-regression | |||||||
|---|---|---|---|---|---|---|---|---|
| Covariable | N | DOR (95% CI) | Covariable | Coefficient | Standard error | RDOR (95% CI) | P | |
| Age | 0.060 | 0.0462 | 1.06 (0.95–1.19) | 0.2423 | ||||
| Europe | 3 | 11.81 (4.31–32.35) | 0% | Prevalence | 0.003 | 0.0232 | 1.00 (0.95–1.06) | 0.9106 |
| Asia | 6 | 59.77 (19.72–181.11) | 10.6% | Sample size (n) | -0.018 | 0.0100 | 0.98 (0.96–1.01) | 0.1152 |
| Magnetic field strength | -0.222 | 1.1056 | 0.80 (0.05–11.98) | 0.8476 | ||||
| Parotid gland | 5 | 16.06 (6.62–38.95) | 0% | |||||
| Other | 4 | 89.43 (15.83-505-17) | 40.1% | |||||
| 9 | 30.76 (12.73–74.34) | 25.2% | ||||||
| Age | 0.087 | 0.0454 | 1.09 (0.94–1.26) | 0.1505 | ||||
| Salivary glands | 4 | 75.04 (27.89–201.96) | 0% | Prevalence | -0.037 | 0.0200 | 0.96 (0.92–1.01) | 0.1213 |
| Other | 3 | 29.99 (6.98–128.80) | 23.7% | Sample size (n) | 0.003 | 0.0164 | 1.00 (0.96–1.05) | 0.8449 |
| 9 | 48.12 (22.44–103.21) | 0% | Magnetic field strength | -0.018 | 0.0729 | 0.98 (0.91–1.18) | 0.8165 | |
| Age | -0.205 | 0.1052 | 0.81 (0.64–1.04) | 0.0868 | ||||
| Asia | 4 | 21.40 (11.05–41.44) | 0% | Prevalence | -0.022 | 0.0356 | 0.98 (0.91–1.06) | 0.5569 |
| Americas | 2 | 11.36 (4.20–30.70) | 11% | Sample size (n) | -0.016 | 0.0094 | 0.98 (0.96–1.00) | 0.1191 |
| Europe | 7 | 39.45 (11.79–132.03) | 61.7% | Magnetic field strength | -1.129 | 0.4141 | 0.32 (0.13–0.82) | |
| Parotid gland | 11 | 23.48 (11.91–46.29) | 50.4% | |||||
| Salivary glands | 2 | 34.11 (9.60-121-10) | 0% | |||||
| 13 | 23.98 (13.26–43.37) | 43.2% | ||||||